Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Portfolio Pulse from
Alkermes is transitioning from royalty-based revenues to proprietary product sales, with strong growth in Lybalvi, Vivitrol, and Aristada. The company is also developing ALKS 2680, a promising drug for narcolepsy and hypersomnia, targeting a $7.3 billion market by 2032. With substantial liquidity and positive cash flow, Alkermes is well-positioned to fund its R&D and operations.
November 24, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alkermes is seeing strong growth in its proprietary products, Lybalvi, Vivitrol, and Aristada, and is developing ALKS 2680 for a large market opportunity. The company has strong liquidity and positive cash flow, supporting its R&D and operations.
Alkermes' shift to proprietary product sales is driving revenue growth, and the development of ALKS 2680 presents a significant market opportunity. The company's strong liquidity and positive cash flow enhance its ability to fund ongoing R&D and operations, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100